Context sidebar

Summary report on authorisation

With immediate effect, Swissmedic will not be publishing any new Summary reports on authorisation in order to focus its resources on its core business. The situation will be reassessed at the end of 2027. 

Since the entry into force of the revised therapeutic products legislation on 1 January 2019, Swissmedic has published summarised assessment reports, known as the “Swiss Public Assessment Report” (SwissPAR for short).

In addition to this, Swissmedic publishes an abridged version of the SwissPAR known as the “Summary report on authorisation”. This is intended to make Swissmedic's authorisation decisions comprehensible and transparent to the wider public.

The Summary report on authorisation is based on the content of the published SwissPAR and the officially approved product information texts.

The following list also includes Summary reports on authorisation for medicinal products that are no longer authorised. These Summary reports are indicated as “no longer authorised” in the relevant description. You can find an overview of currently authorised medicinal products here.

The Summary report on authorisation was known as the Public Summary SwissPAR until 1 October 2024. Earlier reports have not been revised.

News

Summary report on authorisation – Ogsiveo®

First authorisation

Summary report on authorisation – Tranylcypromine Rivopharm®

First authorisation

Summary report on authorisation – Abrysvo®

Extension of therapeutic indication (01)

Summary report on authorisation – Opdualag®

Extension of therapeutic indication (01)

Summary report on authorisation – Serum autolog Insel, eye drops®

First authorisation

Suche nach Präparatenamen 

    Suchergebnisse

    0 Ergebnisse gefunden

    Dokumente

    Dokumente

    Sorted...

    Sorted by name of the medicinal product

    A - C

    Summary report on authorisation – Abecma®

    First authorisation

    Summary report on authorisation – Abecma®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Abrysvo®

    First authorisation

    Summary report on authorisation – Abrysvo®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Adtralza®

    First authorisation

    Summary report on authorisation – Agamree®

    First authorisation

    Public Summary SwissPAR – Aklief®

    First authorisation

    Public Summary SwissPAR – Alhemo®

    First authorisation

    Summary report on authorisation – Alhemo®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Altuvoct®

    First authorisation

    Public Summary SwissPAR – Alunbrig®

    First authorisation

    Summary report on authorisation – Alyftrek®

    First authorisation

    Public Summary SwissPAR – Amvuttra®

    First authorisation

    Summary report on authorisation – Amvuttra®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Andembry®

    First authorisation

    Summary report on authorisation – Anzupgo®

    First authorisation

    Public Summary SwissPAR – Aquipta®

    First authorisation

    Public Summary SwissPAR – Arexvy®

    First authorisation

    Public Summary SwissPAR – Aspaveli®

    First authorisation

    Summary report on authorisation – Aspaveli®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Aspaveli®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Awiqli FlexTouch®

    First authorisation

    Summary report on authorisation – Ayvakyt®

    First authorisation

    Summary report on authorisation – AYVAKYT®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Balversa®

    First authorisation

    Public Summary SwissPAR – BCG Apogepha®

    First authorisation

    Summary report on authorisation – BCG-medac®

    First authorisation

    Public Summary SwissPAR – Beovu®

    First authorisation

    Public Summary SwissPAR – Beovu®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Besremi®

    First authorisation

    Public Summary SwissPAR – Beyfortus®

    First authorisation

    Summary report on authorisation – BEYONTTRA®

    First authorisation

    Public Summary SwissPAR – Bimzelx®

    First authorisation

    Summary report on authorisation – Bimzelx®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Bimzelx®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Bimzelx®

    Extension of therapeutic indication (03)

    Public Summary SwissPAR – Blenrep®

    First authorisation - No longer authorised

    Summary report on authorisation – Blenrep®

    First authorisation

    Summary report on authorisation – Blenrep®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Breyanzi®

    First authorisation

    Summary report on authorisation – Breyanzi®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Breyanzi®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Briumvi®

    First authorisation

    Public Summary SwissPAR – Brukinsa®

    First authorisation

    Public Summary SwissPAR – Brukinsa®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Brukinsa®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Bylvay®

    First authorisation

    Public Summary SwissPAR – Cablivi®

    First authorisation

    Public Summary SwissPAR – Cablivi®

    Indication extension (01)

    Public Summary SwissPAR – Calquence®

    First authorisation

    Summary report on authorisation – Calquence®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Camzyos®

    First authorisation

    Summary report on authorisation – CAPVAXIVE®

    First authorisation

    Public Summary SwissPAR – Carbaglu®

    First authorisation

    Summary report on authorisation – Carvykti®

    First authorisation

    Summary report on authorisation – Carvykti®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Casgevy®

    First authorisation

    Public Summary SwissPAR – Cibinqo®

    First authorisation

    Public Summary SwissPAR – Clofara®

    First authorisation

    Public Summary SwissPAR – Colibiogen Oral®

    First authorisation

    Public Summary SwissPAR – Columvi®

    First authorisation

    Public Summary SwissPAR – Comirnaty®

    First authorisation

    Public Summary SwissPAR – Condrosulf Plus®

    First authorisation

    Public Summary SwissPAR – COVID-19 Vaccine Janssen®

    First authorisation - No longer authorised

    D - F

    Summary report on authorisation – DATROWAY®

    First authorisation

    Public Summary SwissPAR – Defitelio®

    First authorisation

    Summary report on authorisation – Desveneurax®

    First authorisation

    Public Summary SwissPAR – Doptelet®

    First authorisation

    Public Summary SwissPAR – Drovelis®

    First authorisation

    Summary report on authorisation – Ebglyss®

    First authorisation

    Public Summary SwissPAR – Ebvallo®

    First authorisation

    Public Summary SwissPAR – Efluelda®

    First authorisation

    Summary report on authorisation – Ekterly®

    First authorisation

    Summary report on authorisation – Elahere®

    First authorisation

    Public Summary SwissPAR – Elfabrio®

    First authorisation

    Public Summary SwissPAR – Elrexfio®

    First authorisation

    Public Summary SwissPAR – Elucirem®

    First authorisation

    Public Summary SwissPAR – ELZONRIS®

    First authorisation

    Summary report on authorisation – Enflonsia®

    First authorisation

    Public Summary SwissPAR – Enhertu®

    First authorisation

    Public Summary SwissPAR – Enhertu®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Enhertu®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Enhertu®

    Extension of therapeutic indication (03)

    Summary report on authorisation – Enhertu®

    Extension of therapeutic indication (04)

    Summary report on authorisation – Enhertu®

    Extension of therapeutic indication (05)

    Summary report on authorisation - Enhertu®

    Extension of therapeutic indication (06)

    Summary report on authorisation – Enjaymo®

    First authorisation

    Summary report on authorisation – Enrylaze®

    First authorisation

    Public Summary SwissPAR – Enspryng®

    First authorisation

    Public Summary SwissPAR – Epidyolex®

    First authorisation

    Public Summary SwissPAR – Epidyolex®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Ervebo®

    First authorisation

    Summary report on authorisation – Ervebo®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Evrysdi®

    First authorisation

    Public Summary SwissPAR – Evrysdi®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Evusheld®

    First authorisation

    Public Summary SwissPAR – Evusheld®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Exkivity®

    First authorisation - No longer authorised

    Summary report on authorisation – Ezmekly®

    First authorisation

    Summary report on authorisation – Fabhalta®

    First authorisation

    Summary report on authorisation – Fabhalta®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Filspari®

    First authorisation

    Summary report on authorisation – Filsuvez®

    First authorisation

    Public Summary SwissPAR – Fluenz Tetra®

    First authorisation

    Summary report on authorisation – 18F-PSMA-1007 ZRP®

    First authorisation

    Summary report on authorisation – Fruzaqla®

    First authorisation

    G - K

    Public Summary SwissPAR – Gavreto®

    First authorisation

    Summary report on authorisation – Givlaari®

    First authorisation

    Summary report on authorisation – Hemgenix®

    First authorisation

    Public Summary SwissPAR – Heparin Sintetica®

    First authorisation

    Public Summary SwissPAR – Hepcludex®

    First authorisation

    Summary report on authorisation – Hepcludex®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Hetronifly®

    First authorisation

    Summary report on authorisation – Hympavzi®

    First authorisation

    Public Summary SwissPAR – Idefirix®

    First authorisation

    Summary report on authorisation – Imaavy®

    First authorisation

    Summary report on authorisation – Imcivree®

    First authorisation

    Public Summary SwissPAR – Imjudo®

    First authorisation

    Public Summary SwissPAR – Inrebic®

    First authorisation

    Summary report on authorisation – Itovebi®

    First authorisation

    Public Summary SwissPAR – Jaypirca®

    First authorisation

    Summary report on authorisation – Jaypirca®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Jemperli®

    First authorisation

    Public Summary SwissPAR – Jemperli®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Jemperli®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Jeraygo®

    First authorisation

    Public Summary SwissPAR – JYNNEOS®

    First authorisation

    Public Summary SwissPAR – Kapruvia®

    First authorisation

    Public Summary SwissPAR – Kerendia®

    First authorisation

    Summary report on authorisation – Kerendia®

    Extension of therapeutic indication (01)

    Summary report on authorisation – KIMMTRAK®

    First authorisation

    Summary report on authorisation – Kisunla®

    First authorisation

    Public Summary SwissPAR – Klisyri®

    First authorisation

    Public Summary SwissPAR – Koselugo®

    First authorisation

    L - N

    Public Summary SwissPAR – Lamzede®

    First authorisation

    Summary report on authorisation – Lazcluze®

    First authorisation

    Summary report on authorisation – Leqvio®

    First authorisation

    Public Summary SwissPAR – Letybo®

    First authorisation

    Summary report on authorisation – Levocalm®

    First authorisation

    Summary report on authorisation – Libmeldy®

    First authorisation

    Summary report on authorisation – Litfulo®

    First authorisation

    Summary report on authorisation – Livmarli®

    First authorisation

    Summary report on authorisation – Livmarli®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – LIVTENCITY®

    First authorisation

    Public Summary SwissPAR – Locametz®

    First authorisation

    Public Summary SwissPAR – Lokelma®

    First authorisation

    Public Summary SwissPAR – Lumykras®

    First authorisation - No longer authorised

    Public Summary SwissPAR – Lunsumio®

    First authorisation

    Public Summary SwissPAR – Lupkynis®

    First authorisation

    Summary report on authorisation – Lutathera®

    First authorisation

    Public Summary SwissPAR – Luxturna®

    First authorisation

    Public Summary SwissPAR – Lyfnua®

    First authorisation

    Summary report on authorisation – Lynkuet®

    First authorisation

    Summary report on authorisation – Lytgobi®

    First authorisation

    Summary report on authorisation – Lyvdelzi®

    First authorisation

    Summary report on authorisation – MenQuadfi®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – MenQuadfi®

    First authorisation

    Public Summary SwissPAR – Mictonorm®

    First authorisation

    Public Summary SwissPAR – milgamma®

    First authorisation

    Public Summary SwissPAR – Minjuvi®

    First authorisation

    Summary report on authorisation – Minjuvi®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Mounjaro®

    First authorisation

    Summary report on authorisation – Mounjaro®

    Extension of therapeutic indication (01)

    Summary report on authorisation – mRESVIA®

    First authorisation

    Summary report on authorisation – mRESVIA®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Nemluvio®

    First authorisation

    Public Summary SwissPAR – NexoBrid®

    First authorisation

    Summary report on authorisation – NexoBrid®

    Extension of therapeutic indication (01)

    Summary report on authorisation – NEXPOVIO®

    First authorisation

    Public Summary SwissPAR – Nexviadyme®

    First authorisation

    Public Summary SwissPAR – Ngenla®

    First authorisation

    Public Summary SwissPAR – Nicardipin Labatec®

    First authorisation

    Public Summary SwissPAR – Nilemdo®

    First authorisation

    Summary report on authorisation – Nilemdo®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Nityr®

    First authorisation

    Public Summary SwissPAR – Nubeqa®

    First authorisation

    Public Summary SwissPAR – Nubeqa®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Nubeqa®

    Extension of therapeutic indication (02)

    Public Summary SwissPAR – Nuceiva®

    First authorisation

    Public Summary SwissPAR – Nuvaxovid®

    First authorisation

    Public Summary SwissPAR – Nuvaxovid®

    Extension of therapeutic indication (01)

    O - R

    Summary report on authorisation – Obgemsa®

    First authorisation

    Summary report on authorisation – Ogsiveo®

    First authorisation

    Summary report on authorisation – Ojemda®

    First authorisation

    Summary report on authorisation – Omjjara®

    First authorisation

    Public Summary SwissPAR – Omvoh®

    First authorisation

    Summary report on authorisation – Omvoh®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Ondexxya®

    First authorisation

    Public Summary SwissPAR – Onpattro®

    First authorisation

    Public Summary SwissPAR – Ontozry®

    First authorisation

    Public Summary SwissPAR – Opdualag®

    First authorisation

    Summary report on authorisation – Opdualag®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Orladeyo®

    First authorisation

    Public Summary SwissPAR – Orserdu®

    First authorisation

    Public Summary SwissPAR – OXLUMO®

    First authorisation

    Public Summary SwissPAR – Padcev®

    First authorisation

    Summary report on authorisation – Padcev®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Palforzia®

    First authorisation

    Summary report on authorisation – Palforzia®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Paxlovid®

    First authorisation

    Summary report on authorisation – Paxlovid®

    Indication extension (01)

    Public Summary SwissPAR – Pemazyre®

    First authorisation

    Summary report on authorisation – Pemazyre®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Pheburane®

    First authorisation

    Summary report on authorisation – Piasky®

    First authorisation

    Public Summary SwissPAR – Piqray®

    First authorisation

    Summary report on authorisation – Pluvicto®/Pluvicto CA®

    First authorisation

    Public Summary SwissPAR – Polivy®

    First authorisation

    Summary report on authorisation – Pombiliti®

    First authorisation

    Public Summary SwissPAR – Ponvory®

    First authorisation

    Public Summary SwissPAR – Poteligeo®

    First authorisation

    Summary report on authorisation – Prevenar 20®

    First authorisation

    Summary report on authorisation – Prevenar 20®

    Extension of therapeutic indication (01)

    Summary report on authorisation – PulmoProDiff®

    First authorisation

    Summary report on authorisation – Pylclari®

    First authorisation

    Summary report on authorisation – Qalsody®

    First authorisation

    Public Summary SwissPAR – Qarziba®

    First authorisation

    Summary report on authorisation – Qdenga®

    First authorisation

    Public Summary SwissPAR – Qinlock®

    First authorisation

    Public Summary SwissPAR – QUVIVIQ®

    First authorisation

    Summary report on authorisation – Radelumin®

    First authorisation

    Public Summary SwissPAR – Rapibloc®

    First authorisation

    Public Summary SwissPAR – Raxone®

    First authorisation

    Public Summary SwissPAR –Regkirona®

    First authorisation - No longer authorised

    Summary report on authorisation – Relfydess®

    First authorisation

    Public Summary SwissPAR – Retsevmo®

    First authorisation

    Summary report on authorisation – Retsevmo®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Rinvoq®

    First authorisation

    Public Summary SwissPAR – Rinvoq®

    Indication extension (01)

    Public Summary SwissPAR – Rinvoq®

    Indication extension (02)

    Public Summary SwissPAR – Rinvoq®

    Indication extension (03)

    Summary report on authorisation – Rinvoq®

    Extension of therapeutic indication (04)

    Summary report on authorisation – Rinvoq®

    Extension of therapeutic indication (05)

    Summary report on authorisation – Rinvoq®

    Extension of therapeutic indication (06)

    Public Summary SwissPAR – Roclanda®

    First authorisation

    Public Summary SwissPAR – Ronapreve®

    First authorisation

    Summary report on authorisation – RoTecPSMA®

    First authorisation

    Public Summary SwissPAR – Rozlytrek®

    First authorisation

    Public Summary SwissPAR – Rubraca®

    First authorisation

    Public Summary SwissPAR – Rukobia®

    First authorisation

    Public Summary SwissPAR – Rybelsus®

    First authorisation

    Summary report on authorisation – Rybelsus®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Rybrevant®

    First authorisation

    Summary report on authorisation – Rybrevant®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Rybrevant®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Rybrevant®

    Extension of therapeutic indication (03)

    Public Summary SwissPAR – Ryeqo®

    First authorisation

    Summary report on authorisation – Ryeqo®

    Extension of therapeutic indication (01)

    Summary report on authorisation – RYSTIGGO®

    First authorisation

    S - U

    Public Summary SwissPAR – Saphnelo®

    First authorisation

    Public Summary SwissPAR – Sarclisa®

    First authorisation

    Summary report on authorisation – Sarclisa®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Sarclisa®

    Extension of therapeutic indication (02)

    Public Summary SwissPAR – Scemblix®

    First authorisation

    Summary report on authorisation – Scemblix®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Scemblix®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Sephience®

    First authorisation

    Summary report on authorisation – Serum autolog Blutspende Zürich, eye drops®

    First authorisation

    Summary report on authorisation – Sérum autologue HOJG, eye drops®

    First authorisation

    Summary report on authorisation – Sérum autologue ICH, eye drops®

    First authorisation

    Summary report on authorisation – Serum autolog Insel, eye drops®

    First authorisation

    Summary report on authorisation – Serum autolog KSGR, eye drops®

    First authorisation

    Summary report on authorisation – Serum autolog LUKS, eye drops®

    First authorisation

    Summary report on authorisation – Serum autolog Universitätsspital Basel, eye drops®

    First authorisation

    Summary report on authorisation – Serum autolog USZ, eye drops®

    First authorisation

    Public Summary SwissPAR – Shingrix®

    First authorisation

    Summary report on authorisation – Skyclarys®

    First authorisation

    Public Summary SwissPAR – Softigyn®

    First authorisation

    Summary report on authorisation – Sogroya®

    First authorisation

    Public Summary SwissPAR – Solmucol Bronchoprotect®

    First authorisation

    Public Summary SwissPAR – Spaverin®

    First authorisation

    Public Summary SwissPAR – Spevigo®

    First authorisation

    Summary report on authorisation – Spevigo®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Spikevax®

    First authorisation

    Public Summary SwissPAR – Spravato®

    First authorisation

    Public Summary SwissPAR – Spravato®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Sunlenca®

    First authorisation

    Public Summary SwissPAR – Sunosi®

    First authorisation

    Public Summary SwissPAR – Supemtek®

    First authorisation

    Summary report on authorisation – SWAN-PSMA-1007®

    First authorisation

    Public Summary SwissPAR – Tabrecta®

    First authorisation

    Public Summary SwissPAR – Talvey®

    First authorisation

    Public Summary SwissPAR – Tavneos®

    First authorisation

    Summary report on authorisation – Tecartus®

    First authorisation

    Summary report on authorisation – Tecartus®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Tecvayli®

    First authorisation

    Summary report on authorisation – Tegsedi®

    First authorisation - no longer authorised

    Public Summary SwissPAR – Tenkasi®

    First authorisation

    Public Summary SwissPAR – Tenkasi®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Tepezza®

    First authorisation

    Public Summary SwissPAR – Tepkinly®

    First authorisation

    Summary report on authorisation – Tepkinly®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Tepmetko®

    First authorisation

    Summary report on authorisation – Tevimbra®

    First authorisation

    Summary report on authorisation – Tevimbra®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Tevimbra®

    Extension of therapeutic indication (02)

    Public Summary SwissPAR – Tezspire®

    First authorisation

    Summary report on authorisation – Tezspire®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Tibsovo®

    First authorisation

    Summary report on authorisation – Transfert de microbiote fécal pour utilisation allogénique CHUV, Hartkapseln mit veränderter Wirkstofffreisetzung®

    First authorisation

    Summary report on authorisation – Transfert de microbiote fécal pour utilisation allogénique CHUV, Rektalsuspension®

    First authorisation

    Summary report on authorisation – Tranylcypromine Rivopharm®

    First authorisation

    Public Summary SwissPAR – Trecondi®

    First authorisation

    Summary report on authorisation – Trecondi®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Trikafta®

    First authorisation

    Public Summary SwissPAR – Trikafta®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Trikafta®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Trikafta®

    Extension of therapeutic indication (03)

    Summary report on authorisation – Trikafta®

    Extension of therapeutic indication (04)

    Public Summary SwissPAR – Triogen®

    First authorisation

    Public Summary SwissPAR – Trodelvy®

    First authorisation

    Summary report on authorisation – Trodelvy®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Truqap®

    First authorisation

    Public Summary SwissPAR – Tukysa®

    First authorisation

    Summary report on authorisation – Tukysa®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Tymlos®

    First authorisation

    Public Summary SwissPAR – Ultomiris®

    First authorisation

    Public Summary SwissPAR – Ultomiris®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Ultomiris®

    Extension of therapeutic indication (02)

    Public Summary SwissPAR – Ultomiris®

    Extension of therapeutic indication (03)

    Summary report on authorisation – Ultomiris®

    Extension of therapeutic indication (04)

    Public Summary SwissPAR – Uplizna®

    First authorisation

    V - Z

    Public Summary SwissPAR – Vaborem®

    First authorisation

    Public Summary SwissPAR – Vabysmo®

    First authorisation

    Public Summary SwissPAR – Vabysmo®

    Estensione dell’indicazione (01)

    Public Summary SwissPAR – Vafseo®

    First authorisation

    Summary report on authorisation – VANFLYTA®

    First authorisation

    Public Summary SwissPAR – Vaxneuvance®

    First authorisation

    Public Summary SwissPAR – Vaxneuvance®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – VAZKEPA®

    First authorisation

    Public Summary SwissPAR – Veklury®

    First authorisation

    Public Summary SwissPAR – Veklury®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Veklury®

    Extension of therapeutic indication (02)

    Summary report on authorisation – Veklury®

    Extension of therapeutic indication (03)

    Summary report on authorisation – Velsipity®

    First authorisation

    Summary report on authorisation – Veoza®

    First authorisation

    Public Summary SwissPAR – Verdye®

    First authorisation

    Public Summary SwissPAR – Verquvo®

    First authorisation

    Public Summary SwissPAR – Vocabria®

    First authorisation

    Summary report on authorisation – Vocabria®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Voranigo®

    First authorisation

    Summary report on authorisation – Voxzogo®

    First authorisation

    Summary report on authorisation – Voydeya®

    First authorisation

    Public Summary SwissPAR – Vydura®

    First authorisation

    Public Summary SwissPAR – Vyepti®

    First authorisation

    Summary report on authorisation – Vyloy®

    First authorisation

    Public Summary SwissPAR – Vyndaqel®

    First authorisation

    Summary report on authorisation – Vyvgart®

    First authorisation

    Summary report on authorisation – Vyvgart®

    Estensione dell’indicazione (01)

    Summary report on authorisation – Wainzua®

    First authorisation

    Public Summary SwissPAR – Welireg®

    First authorisation

    Summary report on authorisation – Welireg®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Winrevair®

    First authorisation

    Summary report on authorisation – Winrevair®

    Indication extension (01)

    Public Summary SwissPAR – Xenpozyme®

    First authorisation

    Public Summary SwissPAR – Xevudy®

    First authorisation

    Public Summary SwissPAR – Xofluza®

    First authorisation

    Public Summary SwissPAR – Xofluza®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Xofluza®

    Extension of therapeutic indication (02)

    Public Summary SwissPAR – Xospata®

    First authorisation

    Summary report on authorisation – Yorvipath®

    First authorisation

    Summary report on authorisation – Yselty®

    First authorisation

    Public Summary SwissPAR – Zeposia®

    First authorisation

    Public Summary SwissPAR – Zeposia®

    Extension of therapeutic indication (01)

    Public Summary SwissPAR – Zepzelca®

    First authorisation

    Summary report on authorisation – Zepzelca®

    Extension of therapeutic indication (01)

    Summary report on authorisation – Zilbrysq®

    First authorisation

    Summary report on authorisation – Zolgensma®

    First authorisation

    Summary report on authorisation – ZYNYZ®

    First authorisation

    Summary report on authorisation – ZYNYZ®

    Extension of therapeutic indication (01)

    Last modification 30.09.2024

    Top of page